BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Panfen E, Fancher M, Sinz M, Marathe P, Shen H. Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. Mol Pharmaceutics 2019;16:2342-53. [DOI: 10.1021/acs.molpharmaceut.8b01226] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Storelli F, Yin M, Kumar AR, Ladumor MK, Evers R, Chothe PP, Enogieru OJ, Liang X, Lai Y, Unadkat JD. The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans. Pharmacology & Therapeutics 2022;238:108271. [DOI: 10.1016/j.pharmthera.2022.108271] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Maeda K, Sugiyama Y. IN VITRO–IN VIVO SCALE‐UP OF DRUG TRANSPORT ACTIVITIES. Drug Transporters 2022. [DOI: 10.1002/9781119739883.ch22] [Reference Citation Analysis]
3 Tirona RG, Kim RB. ORGANIC ANION TRANSPORTING POLYPEPTIDES OATP. Drug Transporters 2022. [DOI: 10.1002/9781119739883.ch5] [Reference Citation Analysis]
4 Hanke N, Gómez-Mantilla JD, Ishiguro N, Stopfer P, Nock V. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions. Pharm Res 2021;38:1645-61. [PMID: 34664206 DOI: 10.1007/s11095-021-03109-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, 't Hart LM, Giacomini KM, Pearson ER; for MetGen Plus, for the DIRECT Consortium., MetGen Plus investigators:. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-82. [PMID: 34607834 DOI: 10.2337/dc21-1152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
6 Jala A, Ponneganti S, Vishnubhatla DS, Bhuvanam G, Mekala PR, Varghese B, Radhakrishnanand P, Adela R, Murty US, Borkar RM. Transporter-mediated drug-drug interactions: advancement in models, analytical tools, and regulatory perspective. Drug Metab Rev 2021;:1-36. [PMID: 33980079 DOI: 10.1080/03602532.2021.1928687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Modiwala M, Jadav T, Sahu AK, Tekade RK, Sengupta P. A Critical Review on Advancement in Analytical Strategies for the Quantification of Clinically Relevant Biological Transporters. Crit Rev Anal Chem 2021;:1-15. [PMID: 33691566 DOI: 10.1080/10408347.2021.1891859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang Y, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, ‘t Hart LM, Giacomini KM, Pearson ER. Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene <i>SLCO1B1</i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. SSRN Journal. [DOI: 10.2139/ssrn.3795315] [Reference Citation Analysis]
9 Nguyen JT, Tian DD, Tanna RS, Hadi DL, Bansal S, Calamia JC, Arian CM, Shireman LM, Molnár B, Horváth M, Kellogg JJ, Layton ME, White JR, Cech NB, Boyce RD, Unadkat JD, Thummel KE, Paine MF. Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. Clin Pharmacol Ther 2021;109:1342-52. [PMID: 33174626 DOI: 10.1002/cpt.2107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Sane R, Cheung KWK, Kovács P, Farasyn T, Li R, Bui A, Musib L, Kis E, Plise E, Gáborik Z. Calibrating the In Vitro–In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models. Drug Metab Dispos 2020;48:1264-70. [DOI: 10.1124/dmd.120.000149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Zhang F, Duan Y, Wei Y, Zhang J, Ma X, Tian H, Wang X, Saad AAA, Li B, Wu X. The inhibition of hepatic Pxr-Oatp2 pathway mediating decreased hepatic uptake of rosuvastatin in rats with high-fat diet-induced obesity. Life Sci 2020;257:118079. [PMID: 32668326 DOI: 10.1016/j.lfs.2020.118079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhang Y, Holenarsipur VK, Kandoussi H, Zeng J, Mariappan TT, Sinz M, Shen H. Detection of Weak Organic Anion–Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans. Drug Metab Dispos 2020;48:841-8. [DOI: 10.1124/dmd.120.000076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
13 Zhang Y, Chen C, Chen SJ, Chen XQ, Shuster DJ, Puszczalo PD, Fancher RM, Yang Z, Sinz M, Shen H. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression. J Pharmacol Exp Ther 2020;375:139-51. [PMID: 32719071 DOI: 10.1124/jpet.120.000139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Taguchi T, Masuo Y, Futatsugi A, Kato Y. Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics. Drug Metab Dispos 2020;48:750-8. [PMID: 32616544 DOI: 10.1124/dmd.120.000020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Darney K, Turco L, Buratti F, Di Consiglio E, Vichi S, Roudot A, Béchaux C, Testai E, Dorne J, Lautz L. Human variability in influx and efflux transporters in relation to uncertainty factors for chemical risk assessment. Food and Chemical Toxicology 2020;140:111305. [DOI: 10.1016/j.fct.2020.111305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
16 Gu X, Wang L, Gan J, Fancher RM, Tian Y, Hong Y, Lai Y, Sinz M, Shen H. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. Drug Metab Dispos 2020;48:724-34. [DOI: 10.1124/dmd.120.090670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Izumi S, Nozaki Y, Kusuhara H, Hotta K, Mochizuki T, Komori T, Maeda K, Sugiyama Y. Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. Mol Pharm 2020;17:722-3. [PMID: 31961160 DOI: 10.1021/acs.molpharmaceut.0c00025] [Reference Citation Analysis]
18 Nozaki Y, Izumi S. Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. Drug Metabolism and Pharmacokinetics 2020;35:56-70. [DOI: 10.1016/j.dmpk.2019.11.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]